Benzyl Benzoate-Loaded Microemulsion for Topical Applications: Enhanced Dermatokinetic Profile and Better Delivery Promises

AAPS PharmSciTech

Volumn 17, Issue 5, 2016, Pages 1221-1231

  Sharma, Gajanand ^a   Dhankar, Geeta ^a   Thakur, Kanika ^a   Raza, Kaisar ^b   Katare, O P ^a  

^a PANJAB UNIVERSITY   (India)

^b CENTRAL UNIVERSITY OF RAJASTHAN   (India)

Author keywords

colloidal delivery; dermal availability; drug delivery; hydrogel; nanoemulsion; retention; scabies

Indexed keywords

ALCOHOL; BENZYL BENZOATE; OIL; PHOSPHOLIPID; POLYSORBATE 80; SURFACTANT; BENZOIC ACID DERIVATIVE; DRUG CARRIER; EMULSION; HYDROGEL; NANOPARTICLE; POLYSORBATE;

ABDOMINAL SKIN; ANIMAL TISSUE; AQUEOUS SOLUTION; AREA UNDER THE CURVE; ARTICLE; BIOCOMPATIBILITY; CHEMICAL COMPOSITION; CHEMICAL REACTION KINETICS; CONTROLLED STUDY; DERMATOKINETIC; DERMIS; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG RETENTION; DRUG SAFETY; DRUG STABILITY; DRUG STRUCTURE; EPIDERMIS; EX VIVO STUDY; EXTERNAL PHASE; HISTOPATHOLOGY; HYDROGEL; MALE; MAXIMUM PLASMA CONCENTRATION; MEMBRANE TRANSPORT; MICROEMULSION; MICROSCOPY; MOUSE; NONHUMAN; OILY PHASE; PARTICLE SIZE; PH; PHASE TRANSITION; PRIORITY JOURNAL; PROCESS OPTIMIZATION; PSEUDO TERNARY PHASE; REFRACTION INDEX; SKIN; SKIN PERMEATION; SUSTAINED DRUG RELEASE; TIME TO MAXIMUM PLASMA CONCENTRATION; TRANSMISSION ELECTRON MICROSCOPY; ZETA POTENTIAL; ADMINISTRATION AND DOSAGE; ANIMAL; BIOAVAILABILITY; CHEMISTRY; EMULSION; MEDICINAL CHEMISTRY; METABOLISM; PERMEABILITY; PROCEDURES; SKIN ABSORPTION; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ANIMALS; BENZOATES; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRUG STABILITY; EMULSIONS; HYDROGEL; MALE; MICE; NANOPARTICLES; PARTICLE SIZE; PERMEABILITY; POLYSORBATES; SKIN; SKIN ABSORPTION; SURFACE-ACTIVE AGENTS;

EID: 84949948801     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-015-0464-0     Document Type: Article

References (48)

1. Chosidow O. Scabies and pediculosis. Lancet. 2000;355:819–26.
2. Hengge UR, Currie BJ, Jäger G, Lupi O, Schwartz RA. Scabies: a ubiquitous neglected skin disease. Lancet Infect Dis. 2006;6(12):769–79.
3. Taplin D, Meinking TL, Chen JA, Sanchez R. Comparison of crotamiton 10% cream (Eurax) and permethrin 5% cream (Elimite) for the treatment of scabies in children. Pediatr Dermatol. 1990;7:67–73.
4. Guggisberg D, de Viragh PA, Constantin C, Panizzon RG. Norwegian scabies in a patient with acquired immunodeficiency syndrome. Dermatology. 1998;197:306–8.
5. Roberts LJ, Huffam SE, Walton SF, Currie BJ. Crusted scabies: clinical and immunological findings in seventy-eight patients and a review of the literature. J Infect. 2005;50:375–81.
6. Walton SF, Currie BJ. Problems in diagnosing scabies, a global disease in human and animal populations. Clin Microbiol Rev. 2007;20(2):268–79.
7. McCarthy JS, Kemp DJ, Walton SF, Currie BJ. Scabies: more than just an irritation. Postgrad Med J. 2004;80:382–7.
8. Tomalik-Scharte D, Lazar A, Meins J, Bastian B, Ihrig M, Wachall B, et al. Dermal absorption of permethrin following topical administration. Eur J Clin Pharmacol. 2005;61:399–404.
9. Bachewar NP, Thawani VR, Mali SN, Gharpure KJ, Shinghade VP, Dakhale GN. Comparison of safety, efficacy, and cost effectiveness of benzyl benzoate, permethrin, and ivermectin in patients of scabies. Indian J Pharmacol. 2009;41(1):9–14.
10. Alberici E, Pagani L, Ratti G, Viale P. Ivermectin alone or in combination with benzyl benzoate in the treatment of human immunodeficiency virus-associated scabies. Br J Dermatol. 2000;142:969–72.
11. Karthikeyan K. Treatment of scabies: newer perspectives. Postgrad Med J. 2005;81:7–10.
12. Glaziou P, Cartel JL, Alzieu P, Briot C, Moulia-Pelat JP, Martin PM. Comparison of ivermectin and benzyl benzoate for treatment of scabies. Trop Med Parasitol. 1993;44:331–2.
13. Currie BJ, Harumal P, McKinnon M, Walton SF. First documentation of in-vivo and in-vitro ivermectin resistance in Sarcoptes scabiei. Clin Infect Dis. 2004;39:8–12.
14. Walton SF, Myerscough MR, Currie BJ. Studies in-vitro on the relative efficacy of current acaricides for Sarcoptes scabiei varhominis. Trans R Soc Trop Med Hyg. 2000;94:92–6.
15. Yewale C, Baradia D, Vhora I, Misra A. Proteins: emerging carrier for delivery of cancer therapeutics. Expert Opin Drug Deliv. 2013;10:1429–48.
16. Katare OP, Raza R, Singh B, Dogra S. Novel drug delivery systems in topical treatment of psoriasis: rigors and vigors. Indian J Dermatol Venereol. 2010;76:612–21.
17. Raza K, Negi P, Takyar S, Shukla A, Amarji B, Katare OP. Novel dithranol phospholipid microemulsion for topical application:development, characterization and percutaneous absorption studies. J Microencapsul. 2011;28(3):190–9.
18. Kreilgaard M. Influence of microemulsions on cutaneous drug delivery. Adv Drug Deliv Rev. 2002;254:77–98.
19. Baboota S, Al-Azaki A, Kohli K, Ali J, Dixit N, Shakeel F. Development and evaluation of a microemulsion formulation for transdermal delivery of terbinafine. J Pharm Sci Technol. 2007;61:276–85.
20. Chen H, Mou D, Du D, Chang X, Zhu D, Liu J, et al. Hydrogel thickened microemulsion for topical administration of drug molecule at an extremely low concentration. Int J Pharm. 2007;341:78–84.
21. Lawrence MJ, Rees GD. Microemulsion-based media as novel drug delivery systems. Adv Drug Deliv Rev. 2000;45:89–121.
22. Kamal MA, Iimura N, Nabekura T, Kitagawa S. Enhanced skin permeation of diclofenac by ion-pair formation and further enhancement by microemulsion. Chem Pharm Bull. 2007;55:368–71.
23. Peltola S, Saarinen-Savolainen P, Kiesvaara J, Suhonen TM, Urtti A. Microemulsions for topical delivery of estradiol. Int J Pharm. 2003;254:99–107.
24. DiBiase M, Rhodes C. Formulation and evaluation of epidermal growth factor in Pluronic-127 gel. Drug Dev Ind Pharm. 1996;22(8):823–31.
25. Yeon S, Chul J, Moo Y. Poly(ethylene oxide)-poly(ethylene oxide)/ ply(∈ − caprolactone) (PCL) amphiphilic block copolymeric nanospheres: Thermo-responsive drug release behaviours. J Control Rel. 2000;65:345–58.
26. Miyazaki S, Tobiyama T, Takada M, Attwood D. Percutaneous absorption of indomethacin from Pluronic F-127 gels in rats. J Pharm Pharmacol. 1995;47:455–7.
27. Escobar-Chávez JJ, López-Cervantes M, Naïk A, Kalia YN, Quintanar-Guerrero D, Ganem-Quintanar D. Applications of thermoreversible Pluronic F-127 gels in Pharmaceutical Formulations. J Pharm Pharm Sci. 2006;9(3):339–58.
28. Kawakami K, Yoshikawa T, Moroto EK, Takahashi K, Nishihara Y, Masuda K. Microemulsion formulation for enhanced absorption of poorly soluble drugs I. Prescription design. J Control Release. 2002;81:65–74.
29. Tansel C, Nursin G. Microemulsions. J Fac Pharm Ank. 1997;26(2):95–108.
30. Agarwal R, Katare OP, Vyas SP. Preparation and in-vitro evaluation of liposomal/niosomal delivery systems for antipsoriatic drug dithranol. Int J Pharm. 2001;228(1–2):43–52.
31. Raza K, Singh B, Lohan S, Sharma G, Negi P, Yachha Y, et al. Nano-lipoidal carriers of tretinoin with enhanced percutaneous absorption, photostability, biocompatibility and anti-psoriatic activity. Int J Pharm. 2013;456:65–72.
32. Singh B, Mehta G, Kumar R, Bhatia A, Ahuja N, Katare OP. Design, development and optimization of nimuslide-loaded liposomal systems for topical applications. Curr Drug Deliv. 2005;2:143–53.
33. Al Abood RM, Talegaonkar S, Tariq M, Ahmad MJ. Microemulsion as a tool for the transdermal delivery of ondansetron for the treatment of chemotherapy induced nausea and vomiting. Colloids Surf B: Biointerfaces. 2013;101:143–51.
34. Guth K, Schäfer-Korting M, Fabian E, Landsiedel R, van Ravenzwaay B. Suitability of skin integrity tests for dermal absorption studies in vitro. Toxicol In Vitro. 2015;29(1):113–23.
35. Negi P, Singh B, Sharma G, Beg S, Raza K, Katare OP. Phopholipid microemulsion-based hydrogel for enhanced topical delivery of lidocaine and prilocaine: QbD-based development and evaluation. Drug Deliv. 2014;3:1–17.
36. Kogan A, Garti N. Microemulsions as transdermal drug delivery vehicles. Adv Colloid Interface Sci. 2006;123–126:369–85.
37. Trotta M, Cavalli R, Uzagio E, Gasco MR. Phase behaviour of microemulsion systems containing lecithin and lysolecithin as surfactants. Int J Pharm. 1996;143:67–73.
38. Raza K, Singh B, Singla S, Wadhwa S, Garg B, Chhibber S, et al. Nanocolloidal carriers of isotretinoin: antimicrobial activity against Propionibacterium acnes and dermatokinetic modeling. Mol Pharm. 2013;10:1958–63.
39. Guterres SS, Weiss V, de Lucca FL, Pohlmann AR. Influence of benzyl benzoate as oil core on the physicochemical properties of spray-dried powders from polymeric nanocapsules containing indomethacin. Drug Deliv. 2000;7(4):195–9.
40. Zarur AJ, Ying JY. Reverse microemulsion synthesis of nanostructured complex oxides for catalytic combustion. Nature. 2000;403:65–7.
41. Gao ZG, Choi HG, Shin HJ. Physicochemical characterization and evaluation of a microemulsion system for oral delievery of cyclosporin A. Int J Pharm. 1998;161:75–86.
42. Kim CK, Ryuu SA, Park KM, Lim SJ. Preparation and physiochemical characterization of phase inverted water: oil microemulsion containing cyclosporine A. Int J Pharm. 1997;147:131–4.
43. Philip AK, Pathak K. Wet process-induced phase-transited drug delivery system: a means for achieving osmotic, controlled, and level A IVIVC for poorly water-soluble drug. Drug Dev Ind Pharm. 2008;34:735–43.
44. Cilek A, Celebi N, Tirnaksiz F. Lecithin-based microemulsion of a peptide for oral administration: preparation, characterization, and physical stability of the formulation. Drug Deliv. 2006;13:19–24.
45. Rigg PC, Barry BW. Shed snake skin and hairless mouse skin as model membranes for human skin during permeation studies. J Invest Dermatol. 1990;94:235–40.
46. Hathout RM, Mansour S, Mortada ND, Geneidi AS, Guy RH. Uptake of microemulsion components into the stratum corneum and their molecular effects on skin barrier function. Mol Pharm. 2010;7:1266–73.
47. Moghadam SH, Saliaj E, Wettig SD, Dong C, Ivanova MV, Huzil JT, et al. Effect of chemical permeation enhancers on stratum corneum barrier lipid organizational structure and interferon alpha permeability. Mol Pharm. 2013;10(6):2248–60.
48. Uchino T, Lefeber F, Gooris G, Bouwstra J. Characterization and skin permeation of ketoprofen-loaded vesicular systems. Eur J Pharm Biopharm. 2014;86(2):156–66.